Related Experiment Videos
Methylene blue: a reliable and practical marker for validating compliance on the DST
The Journal of Clinical Psychiatry
|June 1, 1987
Summary
Methylene blue (MB) combined with dexamethasone reliably confirms patient compliance during dexamethasone suppression tests (DST). This safe and practical method validates DST results without affecting cortisol or dexamethasone levels.
Area of Science:
- Endocrinology
- Clinical Chemistry
- Pharmacology
Background:
- Accurate interpretation of dexamethasone suppression tests (DST) relies on confirmed patient compliance with dexamethasone ingestion.
- Current methods for verifying compliance can be impractical or invasive.
Purpose of the Study:
- To evaluate the efficacy and safety of methylene blue (MB) as a compliance marker in DST.
- To determine if MB affects DST outcomes, including plasma cortisol and dexamethasone levels.
Main Methods:
- A double-blind study involving 13 subjects.
- Methylene blue (50 mg) was co-administered with dexamethasone (1 mg) in single capsules.
- Urinary color change and plasma hormone levels were assessed post-ingestion.
Main Results:
- The co-administration of MB with dexamethasone resulted in a blue-green urinary color, reliably indicating compliance in 100% of participants.
- Methylene blue did not interfere with DST results, showing no significant impact on plasma cortisol or plasma dexamethasone concentrations.
Conclusions:
- Combining methylene blue with dexamethasone provides a safe, reliable, and practical method for validating patient compliance during DST.
- This approach offers a superior alternative to plasma dexamethasone level determination for compliance monitoring.